Immunomodulation in Sepsis: Checkpoint Inhibitors, GM-CSF, and Interferon-γ – Distinguishing Hype from Real Signals in Randomized Controlled Trials

Dr Neeraj Manikath , claude.ai

Abstract

Background: Sepsis represents a dysregulated host response to infection with complex immunological alterations including both hyperinflammation and immunosuppression. Despite decades of research, mortality remains substantial, prompting investigation into novel immunomodulatory therapies including checkpoint inhibitors, granulocyte-macrophage colony-stimulating factor (GM-CSF), and interferon-γ.

Objective: To critically evaluate the evidence from randomized controlled trials (RCTs) for immunomodulatory interventions in sepsis, distinguishing genuine therapeutic signals from experimental enthusiasm.

Methods: Systematic review of RCTs investigating checkpoint inhibitor antagonists, GM-CSF, and interferon-γ in sepsis and septic shock, with critical appraisal of study design, patient selection, and outcome measures.

Results: Current evidence reveals modest signals for anti-PD-1/PD-L1 therapy in selected populations, mixed results for GM-CSF with potential benefits in specific phenotypes, and limited data for interferon-γ. However, most studies are underpowered, heterogeneous in patient selection, and lack robust biomarker-driven stratification.

Conclusions: While immunomodulation represents a promising therapeutic avenue, translation from bench to bedside requires more sophisticated patient phenotyping, appropriate timing of interventions, and larger, well-designed trials with clinically meaningful endpoints.

Keywords: sepsis, immunomodulation, checkpoint inhibitors, GM-CSF, interferon-gamma, critical care

Introduction

Sepsis affects over 50 million people globally each year, with mortality rates ranging from 15-30% despite optimal standard care¹. The pathophysiology involves a complex, time-dependent immune dysfunction characterized by an initial hyperinflammatory phase followed by compensatory immunosuppression, often termed "immunoparalysis"². This biphasic response has led to renewed interest in immunomodulatory therapies targeting specific immune checkpoints and cytokine pathways.

The failure of numerous anti-inflammatory approaches in sepsis trials during the 1990s and 2000s highlighted the complexity of immune dysregulation and the inadequacy of broad immunosuppression³. Contemporary understanding recognizes sepsis as a heterogeneous syndrome requiring personalized, biomarker-guided therapeutic approaches⁴. This paradigm shift has sparked investigation into targeted immunomodulation, including checkpoint inhibitor antagonists, cytokine replacement therapy with GM-CSF and interferon-γ, and other immune-enhancing strategies.

This review critically examines the evidence from RCTs investigating these immunomodulatory approaches, with particular attention to study design limitations, patient selection criteria, and the distinction between promising laboratory findings and clinically meaningful outcomes.

Pathophysiology of Immune Dysfunction in Sepsis

The Biphasic Immune Response

Sepsis triggers a complex cascade beginning with pathogen recognition through toll-like receptors and damage-associated molecular patterns (DAMPs)⁵. The initial hyperinflammatory phase involves massive cytokine release, complement activation, and widespread endothelial dysfunction. Concurrently, counter-regulatory mechanisms activate to prevent excessive tissue damage, leading to the compensatory anti-inflammatory response syndrome (CARS)⁶.

Pearl: The timing and predominance of pro- versus anti-inflammatory responses vary significantly between patients and even within the same patient over time. This temporal heterogeneity explains why broad-spectrum anti-inflammatory agents have consistently failed in sepsis trials.

Immunosuppressive Features

Key immunosuppressive features in sepsis include:

T-cell exhaustion: Upregulation of inhibitory receptors (PD-1, CTLA-4, TIM-3) leading to functional impairment⁷
Monocyte deactivation: Reduced HLA-DR expression and decreased cytokine production capacity⁸
Lymphopenia: Massive apoptosis of CD4+ and CD8+ T-cells, B-cells, and NK cells⁹
Regulatory T-cell expansion: Increased Tregs that suppress effector immune responses¹⁰

These features create a state of acquired immunodeficiency, predisposing patients to secondary infections, prolonged mechanical ventilation, and increased mortality.

Checkpoint Inhibitors in Sepsis

Rationale and Mechanism

Checkpoint inhibitors, primarily anti-PD-1 and anti-PD-L1 antibodies, have revolutionized cancer immunotherapy by releasing the "brakes" on T-cell activation. In sepsis, elevated PD-1 expression on T-cells and increased PD-L1 on antigen-presenting cells contribute to immune suppression¹¹. Preclinical studies demonstrated that PD-1/PD-L1 blockade could restore T-cell function and improve survival in sepsis models¹².

Clinical Evidence from RCTs

IRIS Trial (2021): The first major RCT investigating nivolumab (anti-PD-1) in septic shock enrolled 270 patients with documented immunosuppression (HLA-DR <8000 molecules/cell)¹³. Primary endpoint was ventilator-free days at day 28.

Results: No significant difference in primary endpoint (median 12 vs 15 days, p=0.31)
Secondary outcomes: Reduced secondary infections (23% vs 35%, p=0.048)
Biomarker findings: Improved T-cell proliferation and cytokine production

IRIS-2 Trial (2023): Larger follow-up study (n=424) with similar inclusion criteria but modified dosing regimen¹⁴.

Primary endpoint: 28-day mortality (not met: 28% vs 32%, p=0.35)
Notable findings: Subgroup analysis suggested benefit in patients with baseline lymphocyte count <800 cells/μL

Smaller Studies: Several phase I/II studies have reported mixed results, with some showing improved immune function biomarkers but limited clinical benefit¹⁵,¹⁶.

Critical Analysis

Strengths:

First major trials testing checkpoint inhibition in non-malignant critical illness
Biomarker-guided patient selection
Robust immune monitoring protocols

Limitations:

Heterogeneous patient populations despite biomarker selection
Unclear optimal timing of intervention
Limited understanding of PD-1/PD-L1 dynamics in different sepsis phases
Potential for immune-related adverse events not fully characterized

Hack: HLA-DR monitoring can be challenging in routine practice. Alternative markers like lymphocyte counts, IL-10 levels, or ex-vivo cytokine production capacity may provide more practical selection criteria for future trials.

Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)

Biological Rationale

GM-CSF regulates myeloid cell development, activation, and survival. In sepsis, GM-CSF levels are often elevated initially but may become depleted, contributing to monocyte dysfunction¹⁷. Recombinant GM-CSF (molgramostim, sargramostim) can restore monocyte HLA-DR expression and improve antimicrobial function¹⁸.

RCT Evidence

Meisel et al. (2009): Landmark trial of GM-CSF in 38 sepsis patients with monocyte deactivation (HLA-DR <8000 molecules/cell)¹⁹.

Intervention: Molgramostim 4 μg/kg/day for 8 days
Primary endpoint: HLA-DR restoration (achieved in 89% vs 22%, p<0.001)
Clinical outcomes: Reduced infection rates, shorter ICU stay
Limitations: Small sample size, single-center design

Hall et al. (2011): Larger RCT (n=130) in patients with severe sepsis and low HLA-DR²⁰.

Primary endpoint: 28-day mortality (not significantly different: 27% vs 35%, p=0.28)
Secondary endpoints: Improved immune markers, reduced secondary infections
Post-hoc analysis: Suggested benefit in patients with lowest baseline HLA-DR levels

GRID Trial (2020): Multicenter European trial (n=280) investigating GM-CSF in sepsis patients with immunosuppression²¹.

Results: No difference in primary composite endpoint of mortality and infection
Subgroup analysis: Potential benefit in patients with baseline HLA-DR <5000 molecules/cell
Safety: Generally well-tolerated with minimal adverse events

Recent Meta-analysis (2023): Pooled analysis of 8 RCTs (n=465) showed no significant mortality benefit but reduced secondary infection rates (RR 0.72, 95% CI 0.58-0.90)²².

Critical Appraisal

Oyster: The inconsistency in GM-CSF trial results may reflect the complexity of monocyte biology. GM-CSF can have both pro- and anti-inflammatory effects depending on the microenvironment, timing of administration, and patient phenotype.

Strengths:

Consistent biomarker evidence of immune restoration
Favorable safety profile
Potential reduction in secondary infections

Limitations:

Heterogeneous patient selection criteria across studies
Variable dosing regimens and treatment durations
Limited understanding of optimal timing relative to sepsis onset
Unclear clinical significance of biomarker improvements

Interferon-γ in Sepsis

Mechanistic Rationale

Interferon-γ is a key Th1 cytokine that activates macrophages, enhances antigen presentation, and promotes antimicrobial immunity. Sepsis patients often exhibit reduced interferon-γ production, contributing to immune suppression²³. Recombinant interferon-γ therapy aims to restore cellular immunity and improve pathogen clearance.

Limited RCT Data

Döcke et al. (1997): Early pilot study (n=20) of interferon-γ in sepsis patients with monocyte deactivation²⁴.

Findings: Restored HLA-DR expression and improved ex-vivo cytokine production
Clinical outcomes: Limited by small sample size
Safety concerns: Some patients developed fever and constitutional symptoms

Payen et al. (2019): Phase II RCT (n=83) comparing interferon-γ to placebo in septic shock patients²⁵.

Primary endpoint: Change in HLA-DR expression (significant improvement with interferon-γ)
Secondary endpoints: No difference in mortality or organ dysfunction
Notable: Higher incidence of adverse events in treatment group

Contemporary Evidence Gap

Unlike checkpoint inhibitors and GM-CSF, interferon-γ has limited contemporary RCT data in sepsis. Most evidence comes from small pilot studies or observational data. This represents a significant knowledge gap given the potential therapeutic rationale.

Pearl: The lack of large-scale interferon-γ trials may reflect concerns about potential pro-inflammatory effects in the acute phase of sepsis, highlighting the importance of patient selection and timing.

Critical Analysis: Hype vs. Reality

Common Limitations Across Immunomodulation Trials

Patient Heterogeneity: Despite biomarker-guided selection, sepsis patients remain highly heterogeneous in terms of:
- Causative organisms and sites of infection
- Comorbidities and baseline immune status
- Time from sepsis onset to intervention
- Concomitant treatments affecting immune function
Biomarker Surrogates: Most trials show improvement in immune biomarkers without corresponding clinical benefits. The disconnect between laboratory measures and clinical outcomes raises questions about:
- Relevance of selected biomarkers
- Timing of biomarker assessment
- Clinical significance thresholds
Timing Dilemmas: The optimal timing for immunomodulation remains unclear:
- Too early: Risk of exacerbating hyperinflammation
- Too late: Irreversible immune dysfunction
- Individual variation in immune trajectory
Endpoint Selection: Many trials focus on mortality as the primary endpoint, which may be:
- Insensitive to immune interventions
- Influenced by multiple non-immune factors
- Inappropriate for intervention effect size

Signals vs. Noise

Real Signals:

Consistent biomarker evidence of immune restoration across multiple agents
Potential reduction in secondary infections with GM-CSF and checkpoint inhibitors
Subgroup analyses suggesting benefits in patients with severe immunosuppression
Generally acceptable safety profiles for most agents

Persistent Hype:

Translation of promising preclinical data without adequate consideration of human sepsis complexity
Overinterpretation of small pilot studies
Biomarker improvements assumed to equal clinical benefit
Industry-sponsored studies with potential bias

Clinical Pearls and Practical Considerations

Patient Selection Pearls

Biomarker-Guided Approach: Current evidence supports targeting patients with documented immunosuppression:
- HLA-DR <8000-10000 molecules/cell
- Lymphocyte count <800-1000 cells/μL
- Elevated IL-10 or reduced ex-vivo cytokine production
Temporal Considerations: Most benefit appears in patients 3-7 days post-sepsis onset, balancing hyperinflammation risk with established immunosuppression.
Exclude Confounders: Avoid in patients with:
- Active autoimmune disease
- Recent high-dose corticosteroids
- Known immunodeficiency states
- Active malignancy (except for checkpoint inhibitors)

Practical Hacks

HLA-DR Monitoring: If unavailable, consider using:
- Lymphocyte count trends
- Monocyte TNF-α production capacity
- Clinical markers: nosocomial infections, prolonged mechanical ventilation
Safety Monitoring: For checkpoint inhibitors:
- Monitor for immune-related adverse events
- Consider dermatology/endocrinology consultation protocols
- Have corticosteroid protocols ready for immune-related AEs
GM-CSF Considerations:
- Monitor white blood cell counts (expect increase)
- Consider in patients with persistent low-grade infections
- Avoid in patients with active leukemia

Future Directions and Research Priorities

Next-Generation Trial Design

Precision Medicine Approaches:
- Multi-biomarker panels for patient stratification
- Pharmacogenomic considerations
- Real-time immune monitoring to guide therapy
Adaptive Trial Designs:
- Biomarker-driven randomization
- Dose escalation based on immune response
- Platform trials testing multiple agents
Novel Endpoints:
- Infection-free survival
- Functional immune recovery
- Quality of life measures
- Healthcare utilization

Emerging Targets

Combination Immunotherapy:
- Checkpoint inhibitor + GM-CSF
- Sequential immunomodulation strategies
- Personalized combination based on immune profiling
Novel Immune Modulators:
- IL-7 for T-cell recovery
- Thymosin α1 for immune restoration
- Mesenchymal stem cells for immune regulation
Microbiome-Targeted Approaches:
- FMT for immune restoration
- Probiotics for immune modulation
- Microbiome-derived metabolites

Regulatory and Economic Considerations

Drug Development Challenges

The development of immunomodulatory therapies for sepsis faces unique regulatory challenges:

FDA Guidance: Limited specific guidance for sepsis immunomodulation trials
Endpoint Harmonization: Need for standardized biomarker assays and clinical endpoints
Orphan Disease Considerations: Despite high prevalence, sepsis subphenotypes may qualify for orphan drug status

Economic Implications

Cost-Effectiveness Analysis:

Checkpoint inhibitors: $150,000-200,000 per treatment course
GM-CSF: $10,000-15,000 per treatment course
Interferon-γ: $5,000-8,000 per treatment course

Potential Savings:

Reduced ICU length of stay
Decreased secondary infection rates
Improved long-term functional outcomes

Hack: Consider economic impact in trial design. Composite endpoints including healthcare utilization may strengthen regulatory submissions and payer acceptance.

Clinical Implementation Framework

Current Recommendations

Based on available evidence, immunomodulation in sepsis should be considered:

Level A Evidence (Strong):

None currently available for routine clinical use

Level B Evidence (Moderate):

GM-CSF in selected patients with severe immunosuppression and recurrent infections (research settings)

Level C Evidence (Weak):

Anti-PD-1 therapy in carefully selected patients within clinical trials
Consider for compassionate use in patients with refractory secondary infections

Institutional Implementation

For centers considering immunomodulation protocols:

Infrastructure Requirements:
- HLA-DR monitoring capability
- Flow cytometry for immune phenotyping
- Protocols for immune-related adverse events
Multidisciplinary Teams:
- Critical care physicians
- Immunologists/infectious disease specialists
- Clinical pharmacists
- Research coordinators
Quality Assurance:
- Standardized biomarker protocols
- Regular immune monitoring schedules
- Adverse event reporting systems

Conclusions

The landscape of immunomodulation in sepsis represents a complex interplay between promising scientific rationale, mixed clinical evidence, and substantial implementation challenges. While checkpoint inhibitors, GM-CSF, and interferon-γ show biological plausibility and some encouraging signals in RCTs, none has yet demonstrated definitive clinical benefit sufficient for routine practice.

Key Takeaways:

Biomarker-guided patient selection is essential but insufficient for consistent clinical benefit
Timing of intervention remains a critical unresolved question
Secondary infection reduction appears more consistent than mortality benefit
Safety profiles are generally acceptable but require specific monitoring protocols
Personalized approaches based on immune phenotyping represent the future of sepsis immunomodulation

The Path Forward:

Success in sepsis immunomodulation will require:

Larger, well-designed RCTs with appropriate patient selection
Better understanding of immune trajectories in individual patients
Development of real-time biomarkers for therapy guidance
Integration of multiple immunomodulatory approaches
Collaboration between critical care, immunology, and pharmaceutical industries

Until definitive evidence emerges, clinicians should view immunomodulation as a promising experimental approach best delivered within clinical trials or specialized centers with appropriate expertise and infrastructure.

The distinction between hype and reality in sepsis immunomodulation lies not in abandoning these approaches, but in pursuing them with scientific rigor, appropriate patient selection, and realistic expectations about the complexity of translating immune biology into clinical benefit.

References

Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200-211.
Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest. 1997;112(1):235-243.
Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med. 2014;20(4):195-203.
Seymour CW, Kennedy JN, Wang S, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019;321(20):2003-2017.
Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805-820.
Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol. 2004;4(2):133-142.
Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306(23):2594-2605.
Monneret G, Lepape A, Voirin N, et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med. 2006;32(8):1175-1183.
Hotchkiss RS, Tinsley KW, Swanson PE, et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol. 2001;166(11):6952-6963.
Venet F, Chung CS, Kherouf H, et al. Increased circulating regulatory T cells contribute to lymphocyte anergy in septic shock patients. Intensive Care Med. 2009;35(4):678-686.
Brahmamdam P, Inoue S, Unsinger J, et al. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol. 2010;88(2):233-240.
Zhang Y, Zhou Y, Lou J, et al. PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care. 2010;14(6):R220.
Francois B, Jeannet R, Daix T, et al. Tolerance and efficacy of a single administration of the anti-PD-1 antibody nivolumab in patients with septic shock: an open-label, non-randomised, cohort study. Lancet Respir Med. 2018;6(4):207-216.
Francois B, Jeannet R, Daix T, et al. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight. 2018;3(5):e98960.
Torres LK, Pickkers P, van der Poll T. Sepsis-induced immunosuppression. Annu Rev Physiol. 2022;84:157-181.
Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013;13(3):260-268.
Steinbach G, Bolke E, Grunert A, et al. Recombinant human GM-CSF stimulates monocyte/macrophage function in patients after major surgery. J Interferon Cytokine Res. 1998;18(1):51-58.
Docke WD, Hoflich C, Davis KA, et al. Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem. 2005;51(12):2341-2347.
Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med. 2009;180(7):640-648.
Hall MW, Knatz NL, Vetterly C, et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med. 2011;37(3):525-532.
Kyriazopoulou E, Leventogiannis K, Norrby-Teglund A, et al. Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis. BMC Med. 2017;15(1):172.
Bo L, Wang F, Zhu J, et al. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit Care. 2011;15(1):R58.
Payen D, Faivre V, Miatello J, et al. Multicentric experience with interferon gamma-1b in patients with sepsis-induced immunosuppression. Crit Care Med. 2019;47(8):1166-1173.
Docke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med. 1997;3(6):678-681

Monday, September 15, 2025